Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 02/24 05:35:21 pm
11.46 EUR   -2.05%
02/23 ABLYNX : 23/02/2017 ablynx announces 2016 full year results
02/23 ABLYNX : Announces 2016 full year results
02/20ABLYNX NV : annual earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2011 | 07:05am CET

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
02/23 ABLYNX : 23/02/2017 ablynx announces 2016 full year results
02/23 ABLYNX : Announces 2016 full year results
02/20ABLYNX NV : annual earnings release
02/16 ABLYNX : 16/02/2017 ablynx will announce its 2016 full year results with webcast..
02/16 ABLYNX : Will announce its 2016 full year results with webcast on 23 february 20..
02/16 Ablynx will announce its 2016 full year results with webcast on 23 february 2..
02/09 ABLYNX : 09/02/2017 ablynx to present additional data for its anti-il-6r nanobod..
02/09 ABLYNX : To present additional data for its anti-il-6r nanobody, vobarilizumab, ..
02/06 ABLYNX : 06/02/2017 ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE ..
02/06 ABLYNX : SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES..
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
02/24 Ablynx NV 2016 Q4 - Results - Earnings Call Slides
02/23 Ablynx NV reports FY16 results
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Ablynx NV reports 9M results
2016 ARGENX : The New Ablynx?
Advertisement
Financials (€)
Sales 2017 46,4 M
EBIT 2017 -63,0 M
Net income 2017 -58,2 M
Debt 2017 8,41 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 15,3x
EV / Sales 2018 12,0x
Capitalization 700 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 15,6 €
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX13.87%738
INCYTE CORPORATION21.62%24 852
QUINTILES IMS HOLDINGS..2.72%18 301
CELLTRION, INC.--.--%10 911
LONZA GROUP AG2.67%10 319
SEATTLE GENETICS, INC.19.52%8 939
More Results